We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety. Source
No articles found.
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
ZBP is a biopharmaceutical company that has developed a proprietary technology to ...
ZBP is a biopharmaceutical company that has dev...
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the ...
Salarius Pharmaceuticals, Inc. is a clinical-st...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
Join the National Investor Network and get the latest information with your interests in mind.